Cargando…
Pre-sensitization of Malignant B Cells Through Venetoclax Significantly Improves the Cytotoxic Efficacy of CD19.CAR-T Cells
Chimeric antigen receptor (CAR) T cell therapy has shown promising responses in patients with refractory or relapsed aggressive B-cell malignancies that are resistant to conventional chemotherapy or stem cell transplantation. A potentially combinatorial therapeutic strategy may be the inhibition of...
Autores principales: | Yang, Mingya, Wang, Lei, Ni, Ming, Neuber, Brigitte, Wang, Sanmei, Gong, Wenjie, Sauer, Tim, Sellner, Leopold, Schubert, Maria-Luisa, Hückelhoven-Krauss, Angela, Hong, Jian, Zhu, Lixin, Kleist, Christian, Eckstein, Volker, Müller-Tidow, Carsten, Dreger, Peter, Schmitt, Michael, Schmitt, Anita |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7756123/ https://www.ncbi.nlm.nih.gov/pubmed/33362794 http://dx.doi.org/10.3389/fimmu.2020.608167 |
Ejemplares similares
-
Dual Effects of Cyclooxygenase Inhibitors in Combination With CD19.CAR-T Cell Immunotherapy
por: Yang, Mingya, et al.
Publicado: (2021) -
HDAC Inhibition for Optimized Cellular Immunotherapy of NY-ESO-1-Positive Soft Tissue Sarcoma
por: Gong, Wenjie, et al.
Publicado: (2022) -
Combining selective inhibitors of nuclear export (SINEs) with chimeric antigen receptor (CAR) T cells for CD19-positive malignancies
por: Wang, Sanmei, et al.
Publicado: (2021) -
Tumor-Specific Reactive Oxygen Species Accelerators Improve Chimeric Antigen Receptor T Cell Therapy in B Cell Malignancies
por: Yoo, Hyeon Joo, et al.
Publicado: (2019) -
Evaluation of Production Protocols for the Generation of NY-ESO-1-Specific T Cells
por: Gong, Wenjie, et al.
Publicado: (2021)